Clinical Trials
89 trialsNCT05537766 2026-03-10
ZUMA-25
Gilead Sciences
Phase 2 Terminated
NCT05714345 2026-03-02
EXPAND
Allogene Therapeutics
Phase 2 Terminated
NCT04230265 2026-01-22
Phase 1 Study of UniCAR02-T-CD123 in Patients With Selected CD123 Positive Hematologic Malignancies
AvenCell Therapeutics, Inc.
Phase 1 Terminated
NCT05357027 2026-01-21
HPV16 E6 TCR T Cells for Cervical Carcinoma
TCRCure Biopharma Ltd.
Phase 1/2 Terminated
NCT04770272 2026-01-12
neoMono
Palleos Healthcare GmbH
Phase 2 Terminated
NCT03860844 2025-09-09
ISAKIDS
Sanofi
Phase 2 Terminated
NCT05883449 2025-08-20
LuminICE-203
Affimed GmbH
Phase 2 Terminated
NCT04239092 2025-07-17
9-ING-41 in Pediatric Patients With Refractory Malignancies.
Actuate Therapeutics Inc.
Phase 1 Terminated
NCT04789408 2025-07-11
Study of KITE-222 in Participants With Relapsed/Refractory Acute Myeloid Leukemia
Gilead Sciences
Phase 1 Terminated
NCT04735471 2025-06-18
GLEAN-1
Adicet Therapeutics
Phase 1 Terminated
NCT06128044 2025-06-11
AMpLify
Caribou Biosciences, Inc.
Phase 1 Terminated
NCT03994705 2025-05-15
Descartes-11 in Patients With Relapsed/Refractory Multiple Myeloma
Cartesian Therapeutics
Phase 1 Terminated
NCT05972720 2025-05-15
FIRCE-1
CARGO Therapeutics
Phase 2 Terminated
NCT04029688 2024-12-20
A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Activity of Idasanutlin in Combination With Either Chemotherapy or Venetoclax in Treatment of Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias or Solid Tumors
Hoffmann-La Roche
Phase 1/2 Terminated
NCT03329248 2024-12-12
QUILT-3.060: NANT Pancreatic Cancer Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy
ImmunityBio, Inc.
Phase 1/2 Terminated
NCT05207722 2024-12-12
CYNK-101 in Combination with Trastuzumab and Pembrolizumab in Patients with Locally Advanced Unresectable or Metastatic HER2-Positive Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma
Celularity Incorporated
Phase 1/2 Terminated
NCT02626455 2024-12-11
CHRONOS-4
Bayer
Phase 3 Terminated
NCT03563157 2024-12-11
QUILT 3.071: NANT Colorectal Cancer (CRC) Vaccine
ImmunityBio, Inc.
Phase 1/2 Terminated
NCT04526509 2024-11-26
Master Protocol to Assess Safety and Dose of First Time in Human Next Generation Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Advanced Solid Tumors
Adaptimmune
Phase 1 Terminated
NCT03009058 2024-11-25
MODULATE
Immodulon Therapeutics Ltd
Phase 1/2 Terminated
NCT05943990 2024-11-13
Study of GSK3845097 in Previously Treated Participants With Advanced Synovial Sarcoma and Myxoid/Round Cell Liposarcoma
Adaptimmune
Phase 1 Terminated
NCT06048705 2024-11-13
Study of GSK3901961 In Previously Treated Advanced (Metastatic OR Unresectable) Synovial Sarcoma/ Myxoid/Round Cell Liposarcoma, and Previously Treated Metastatic Non-Small Cell Lung Cancer
Adaptimmune
Phase 1 Terminated
NCT04745832 2024-11-04
Phase 3 Study of Zandelisib (ME-401) in Combination With Rituximab in Patients With iNHL - (COASTAL)
MEI Pharma, Inc.
Phase 3 Terminated
NCT03586869 2024-08-27
QUILT-3.080: NANT Pancreatic Cancer Vaccine
ImmunityBio, Inc.
Phase 1/2 Terminated
NCT03498716 2024-08-21
IMpassion030
Hoffmann-La Roche
Phase 3 Terminated
NCT03743246 2024-08-15
A Study to Evaluate the Safety and Efficacy of JCAR017 in Pediatric Subjects With Relapsed/Refractory (r/r) B-cell Acute Lymphoblastic Leukemia (B-ALL) and B-cell Non-Hodgkin Lymphoma (B-NHL)
Celgene
Phase 1/2 Terminated
NCT03387085 2024-08-09
QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy.
ImmunityBio, Inc.
Phase 1/2 Terminated
NCT03387111 2024-08-05
QUILT-3.090: NANT Squamous Cell Carcinoma (SCC) Vaccine: Subjects With SCC Who Have Progressed
ImmunityBio, Inc.
Phase 1/2 Terminated
NCT04109482 2024-07-22
Trial to Evaluate the Safety and Efficacy of MB-102 in Patients With BPDCN.
Mustang Bio
Phase 1/2 Terminated
NCT04790903 2024-07-11
A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax in Combination With Polatuzumab Vedotin Plus Rituximab (R) and Cyclophosphamide, Doxorubicin, Prednisone (CHP) in Participants With Untreated BCL-2 Immunohistochemistry (IHC)-Positive Diffuse Large B-Cell Lymphoma (DLBCL)
Hoffmann-La Roche
Phase 1 Terminated
NCT03448978 2024-07-01
Autologous CD8+ T-cells Expressing an Anti-BCMA CAR in Patients With Myeloma
Cartesian Therapeutics
Phase 1 Terminated
NCT05000450 2024-06-28
Safety and Efficacy of ALLO-605 an Anti-BCMA Allogeneic CAR T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
Allogene Therapeutics
Phase 1/2 Terminated
NCT04927884 2024-06-12
A Study of Sacituzumab With Chemoimmunotherapy to Treat Advanced Triple-Negative Breast Cancer After Prior Therapies
ImmunityBio, Inc.
Phase 1/2 Terminated
NCT03136406 2024-06-11
QUILT-3.039: NANT Pancreatic Cancer Vaccine: Combination Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy
ImmunityBio, Inc.
Phase 1/2 Terminated
NCT03387098 2024-05-22
QUILT-3.070:Pancreatic Cancer Vaccine: Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy
ImmunityBio, Inc.
Phase 1/2 Terminated
NCT05207514 2024-05-17
Compare the Efficacy and the Safety of Taxotere and Nanoxel M as Neoadjuvant Chemotherapy in Breast Cancer
Samyang Biopharmaceuticals Corporation
Phase 3 Terminated
NCT04633148 2024-04-23
Dose-escalating Trial With UniCAR02-T Cells and PSMA Target Module (TMpPSMA) in Patients With Progressive Disease After Standard Systemic Therapy in Cancers With Positive PSMA Marker
AvenCell Therapeutics, Inc.
Phase 1 Terminated
NCT04548700 2024-03-07
Liposomal Mitoxantrone Hydrochloride Injection,Cyclophosphamide, Vincristine and Prednisone in the Treatment of PTCL
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 1 Terminated
NCT04025216 2024-01-24
A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers
Gilead Sciences
Phase 1 Terminated
NCT03912831 2023-12-26
Study to Evaluate the Safety and Efficacy of KITE-439 in HLA-A*02:01+ Adults With Relapsed/Refractory HPV16+ Cancers
Gilead Sciences
Phase 1 Terminated
NCT03861403 2023-11-30
A Dose Escalation and Expansion Study of TRX518 in Combination With Cyclophosphamide Plus Avelumab in Advanced Solid Tumors
Leap Therapeutics, Inc.
Phase 1 Terminated
NCT03624036 2023-11-18
ZUMA-8
Gilead Sciences
Phase 1 Terminated
NCT02188368 2023-11-03
Pomalidomide for Lenalidomide for Relapsed or Refractory Multiple Myeloma Patients
Oncotherapeutics
Phase 2 Terminated
NCT04023071 2023-10-26
FT516 in Subjects With Advanced Hematologic Malignancies
Fate Therapeutics
Phase 1 Terminated
NCT04245722 2023-10-26
FT596 as a Monotherapy and in Combination With Anti-CD20 Monoclonal Antibodies
Fate Therapeutics
Phase 1 Terminated
NCT03318861 2023-10-19
Study to Evaluate the Safety and Efficacy of KITE-585 in Participants With Relapsed/Refractory Multiple Myeloma
Gilead Sciences
Phase 1 Terminated
NCT03699475 2023-09-29
THRIVE
Bellicum Pharmaceuticals
Phase 2/3 Terminated
NCT04171843 2023-09-21
A Dose-escalation Study to Evaluate the Safety and Clinical Activity of PBCAR269A, With or Without Nirogacestat, in Study Participants With Relapsed/Refractory Multiple Myeloma
Precision BioSciences, Inc.
Phase 1 Terminated
NCT04551885 2023-09-21
FT516 in Combination With Monoclonal Antibodies in Advanced Solid Tumors
Fate Therapeutics
Phase 1 Terminated
NCT04614636 2023-09-21
FT538 in Subjects With Advanced Hematologic Malignancies
Fate Therapeutics
Phase 1 Terminated